Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
about
Prediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature reviewAdvances in the treatment of polyarticular juvenile idiopathic arthritisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentUveitis in juvenile idiopathic arthritisA Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis PatientsAlarmins: awaiting a clinical responseAlarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity.MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromesA phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.Juvenile idiopathic arthritis-associated uveitis.Current medical treatments for juvenile idiopathic arthritis.Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab.Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis.Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications.Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis.Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.The PRINTO criteria for clinically inactive disease in juvenile dermatomyositisCirculating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.Current developments in the use of biomarkers for juvenile idiopathic arthritis.Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositisMeasurement of blood calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis.Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs.HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.Emerging drugs to treat juvenile idiopathic arthritis.Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus.Optimization of pediatric rheumatology therapeutics.Juvenile idiopathic arthritis in the new world of biologics.Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications.Impact of the European paediatric legislation in paediatric rheumatology: past, present and future.Disease activity measures in paediatric rheumatic diseasesS100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis.Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review.Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments.
P2860
Q26991741-3A5C8B70-7803-45EA-8A35-864B482C8A54Q27001017-B971ACD8-8763-404E-A4B0-21BD16FD4692Q28079246-A2C6E287-A733-4432-8103-8B2618D51C67Q28086972-90BDB7EB-E005-4A04-A672-C5106305EC91Q28551075-BA227852-AD1A-47E5-B902-A5C25E7AC452Q30523797-4429AAB8-24F6-4AC3-AEAF-9456F5FBF867Q34086704-C20AFB58-1220-4401-8F32-EB57134DC2C2Q34240472-8B06355F-C3C6-46EF-8761-37E5CE730E08Q34632661-519290DF-746E-4285-A924-1C004E6EF810Q34950552-92C85E41-A049-47E9-B7B8-AC6E0D1896B6Q35294398-97900609-8CF9-4830-8F40-F9FEEBCFF7ADQ35617658-FA1D95C7-A387-4EA8-8ECE-416DCDC24AC7Q35840842-A444CCA0-03D1-493B-8DF3-DD3BA47EFC19Q35870808-9DA735DC-5938-4080-A477-451FF358D7CEQ35926593-E4DFA2E8-5550-4586-9F92-31A3081E25ABQ36067062-68EA744E-1C89-421B-83DC-7198B6C0C6D4Q36266841-9610A0B2-E58F-4D55-8C40-56BAB0A062B1Q36453159-2EC08426-3DEF-4794-B26E-E92ECD34FB36Q36910474-3A7DB9C9-FB0B-489E-99C5-2027A6663457Q37093920-C9B41F47-3B0F-4851-B884-8110ECBA08EAQ37095406-2343E93A-A823-423E-9FA8-74A20B303613Q37293030-465D46C5-5128-4FC0-8370-9CAF06B49895Q37343947-CC8A8BAF-198C-40E2-9043-A9CE0AD60766Q37595918-C28F4EEE-2CF8-498D-9E36-3E88A0E45D9EQ37689900-30D9C83C-E154-40CF-A8A7-6EDA5B884BD6Q37737646-DD80DA0F-E8DB-4699-BABF-62D9A0E927C0Q37775937-09E906C4-6863-4370-B458-9EBA4F726488Q37838731-195A4DE2-47F0-4335-940B-F9633A31DE64Q37866288-0CAF9EC7-3498-4032-B8DF-0FB0031854FEQ37870209-E82B80B5-D7A3-4AF6-8542-E944C2C84487Q37965666-BF06A874-C6EB-44FC-B5CA-0588FFB55907Q37991520-9506C390-9056-4310-9834-E42FE864FFD9Q38104461-BE81A8C9-F80A-4661-A956-A96669E8620CQ38113682-2DF056DF-2AC5-4A69-886A-BF49DDF95D03Q38130348-E40B3B33-9A1C-44A9-8FFC-C08B11B482BAQ38148751-A729B220-D8CC-42A4-B657-990AE36393B4Q38191587-FCCE3008-6FF9-48BC-9142-A67CE65735C3Q38214382-94FA0FE4-6A81-4CBB-9761-F65124B069C3Q38223059-7BC479CF-6E76-4FBD-8983-4DBCACF0A2FCQ38337833-8E907277-D596-406B-85AC-B82E871642EC
P2860
Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Methotrexate withdrawal at 6 v ...... : a randomized clinical trial.
@en
type
label
Methotrexate withdrawal at 6 v ...... : a randomized clinical trial.
@en
prefLabel
Methotrexate withdrawal at 6 v ...... : a randomized clinical trial.
@en
P2093
P50
P356
P1476
Methotrexate withdrawal at 6 v ...... : a randomized clinical trial.
@en
P2093
Alberto Martini
Benito Gonzalez
Dimitrina Mihaylova
Dirk Foell
Fabrizia Corona
Florence Kanakoudi Tsakalidou
Gordana Susic
Helmut Wittkowski
Ivan Foeldvari
Joachim Gerss
P304
P356
10.1001/JAMA.2010.375
P407
P50
P577
2010-04-01T00:00:00Z